Logo image of AYJ.DE

VALNEVA SE (AYJ.DE) Stock Fundamental Analysis

FRA:AYJ - Deutsche Boerse Ag - FR0004056851 - Common Stock - Currency: EUR

2.516  -0.04 (-1.41%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AYJ. AYJ was compared to 67 industry peers in the Biotechnology industry. AYJ may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AYJ is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

AYJ had negative earnings in the past year.
In the past year AYJ has reported a negative cash flow from operations.
In the past 5 years AYJ always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: AYJ reported negative operating cash flow in multiple years.
AYJ.DE Yearly Net Income VS EBIT VS OCF VS FCFAYJ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

With an excellent Return On Assets value of 7.48%, AYJ belongs to the best of the industry, outperforming 88.06% of the companies in the same industry.
AYJ has a Return On Equity of 20.65%. This is amongst the best in the industry. AYJ outperforms 88.06% of its industry peers.
Industry RankSector Rank
ROA 7.48%
ROE 20.65%
ROIC N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
AYJ.DE Yearly ROA, ROE, ROICAYJ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

With an excellent Profit Margin value of 15.08%, AYJ belongs to the best of the industry, outperforming 85.07% of the companies in the same industry.
With a Gross Margin value of 41.01%, AYJ perfoms like the industry average, outperforming 55.22% of the companies in the same industry.
AYJ's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 15.08%
GM 41.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
AYJ.DE Yearly Profit, Operating, Gross MarginsAYJ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

3

2. Health

2.1 Basic Checks

AYJ does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AYJ has been increased compared to 1 year ago.
Compared to 5 years ago, AYJ has more shares outstanding
The debt/assets ratio for AYJ has been reduced compared to a year ago.
AYJ.DE Yearly Shares OutstandingAYJ.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
AYJ.DE Yearly Total Debt VS Total AssetsAYJ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

AYJ has an Altman-Z score of -0.16. This is a bad value and indicates that AYJ is not financially healthy and even has some risk of bankruptcy.
AYJ has a Altman-Z score (-0.16) which is comparable to the rest of the industry.
AYJ has a Debt/Equity ratio of 1.06. This is a high value indicating a heavy dependency on external financing.
AYJ's Debt to Equity ratio of 1.06 is in line compared to the rest of the industry. AYJ outperforms 40.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Altman-Z -0.16
ROIC/WACCN/A
WACC8.55%
AYJ.DE Yearly LT Debt VS Equity VS FCFAYJ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

AYJ has a Current Ratio of 2.61. This indicates that AYJ is financially healthy and has no problem in meeting its short term obligations.
AYJ has a Current ratio (2.61) which is in line with its industry peers.
AYJ has a Quick Ratio of 2.14. This indicates that AYJ is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.14, AYJ perfoms like the industry average, outperforming 56.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.61
Quick Ratio 2.14
AYJ.DE Yearly Current Assets VS Current LiabilitesAYJ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

AYJ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -184.21%.
AYJ shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.86%.
Measured over the past years, AYJ shows a small growth in Revenue. The Revenue has been growing by 6.09% on average per year.
EPS 1Y (TTM)-184.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.63%
Revenue 1Y (TTM)17.86%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%50.31%

3.2 Future

AYJ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 119.91% yearly.
The Revenue is expected to grow by 24.84% on average over the next years. This is a very strong growth
EPS Next Y-597.38%
EPS Next 2Y-69.87%
EPS Next 3Y119.91%
EPS Next 5YN/A
Revenue Next Year6.9%
Revenue Next 2Y17.55%
Revenue Next 3Y26.72%
Revenue Next 5Y24.84%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AYJ.DE Yearly Revenue VS EstimatesAYJ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
AYJ.DE Yearly EPS VS EstimatesAYJ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AYJ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AYJ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AYJ.DE Price Earnings VS Forward Price EarningsAYJ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AYJ.DE Per share dataAYJ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

AYJ's earnings are expected to grow with 119.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-69.87%
EPS Next 3Y119.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AYJ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALNEVA SE

FRA:AYJ (7/11/2025, 7:00:00 PM)

2.516

-0.04 (-1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners23.31%
Inst Owner ChangeN/A
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap213.94M
Analysts83.64
Price Target7.43 (195.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-31.52%
Min EPS beat(2)-115.24%
Max EPS beat(2)52.2%
EPS beat(4)2
Avg EPS beat(4)-8.58%
Min EPS beat(4)-115.24%
Max EPS beat(4)72.74%
EPS beat(8)4
Avg EPS beat(8)-10.16%
EPS beat(12)5
Avg EPS beat(12)-55.58%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.5%
Min Revenue beat(2)-4.78%
Max Revenue beat(2)1.77%
Revenue beat(4)1
Avg Revenue beat(4)-7.74%
Min Revenue beat(4)-14.39%
Max Revenue beat(4)1.77%
Revenue beat(8)4
Avg Revenue beat(8)-2.47%
Revenue beat(12)6
Avg Revenue beat(12)43.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.46%
PT rev (3m)-0.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)3.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.86
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 1.37
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS2.92
BVpS2.13
TBVpS1.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.48%
ROE 20.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 15.08%
GM 41.01%
FCFM N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score5
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.96%
Cap/Sales 6.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.61
Quick Ratio 2.14
Altman-Z -0.16
F-Score5
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-184.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.63%
EPS Next Y-597.38%
EPS Next 2Y-69.87%
EPS Next 3Y119.91%
EPS Next 5YN/A
Revenue 1Y (TTM)17.86%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%50.31%
Revenue Next Year6.9%
Revenue Next 2Y17.55%
Revenue Next 3Y26.72%
Revenue Next 5Y24.84%
EBIT growth 1Y82.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-262.99%
EBIT Next 3Y35.74%
EBIT Next 5Y30.38%
FCF growth 1Y61.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.85%
OCF growth 3YN/A
OCF growth 5YN/A